Inhibition of tyrosine kinases by sunitinib associated with focal segmental glomerulosclerosis lesion in addition to thrombotic microangiopathy
| Autor: | Jorge Martínez-Ara, Pilar Zamora, Olga Costero, Mari Luz Picazo, Rafael Selgas, Sara Romero |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
Male
Pathology medicine.medical_specialty Indoles Lung Neoplasms Thrombotic microangiopathy medicine.drug_class Biopsy Urology Antineoplastic Agents Kidney urologic and male genital diseases Tyrosine-kinase inhibitor Focal segmental glomerulosclerosis Enalapril Renal cell carcinoma Sunitinib medicine Humans Pyrroles Carcinoma Renal Cell Aged Transplantation Glomerulosclerosis Focal Segmental Thrombotic Microangiopathies business.industry Glomerulosclerosis Protein-Tyrosine Kinases medicine.disease Kidney Neoplasms female genital diseases and pregnancy complications Nephrology business Nephrotic syndrome Kidney disease medicine.drug |
| Zdroj: | Nephrology Dialysis Transplantation. 25:1001-1003 |
| ISSN: | 1460-2385 0931-0509 |
| DOI: | 10.1093/ndt/gfp666 |
| Popis: | Sunitinib is an orally administered inhibitor of tyrosine kinases and has become the standard of care for many patients with metastatic renal cell carcinoma. Its use has been associated with renal toxicity in some patients. We report a patient with a metastatic clear-cell renal carcinoma who showed arterial hypertension, nephrotic syndrome and azotaemia 10 months after treatment with sunitinib. The renal biopsy revealed focal segmental glomerulosclerosis (FSGS) in addition to thrombotic microangiopathy (TMA), and the complete syndrome disappeared 6 months after sunitinib withdrawal. To our knowledge, this is the first case of FSGS associated to TMA secondary to sunitinib treatment. We discuss the possible glomerular pathomechanism. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|